Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...

Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $217 ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. More than 150,000 bottles of water have been ...

LONDON — Reversing an earlier decision, European regulators on Thursday recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved, saying that the benefits of the ...

Kids' water bottles are a staple in every parent's armoury, not to mention a requirement for most children to take to school and nursery. We recruited primary school children to help with our ...

A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year. Although it ...